文献速递肝病

慢性肾病不影响特利加压素治疗肝肾综合征-急性肾损伤的疗效

Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome-Acute Kidney Injury.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-11-19

这项多中心回顾性观察研究分析了395例接受白蛋白联合特利加压素治疗的肝肾综合征-急性肾损伤患者,按基线是否合并慢性肾病分层。结果显示合并慢性肾病不影响特利加压素的完全应答率及生存,但慢性肾病组肺水肿发生率更高。

要点

  • 合并慢性肾病不影响特利加压素治疗HRS-AKI的完全应答。
  • 慢性肾病组肺水肿发生率高于无慢性肾病组。
  • 两组30天及1年死亡率、需肾脏替代治疗比例相似。

核心结论

  • 慢性肾病不 adverse 影响特利加压素治疗应答或生存。

研究设计与样本

  • 多中心、回顾性、观察性研究,共纳入395例接受白蛋白/特利加压素治疗的患者,按基线是否存在慢性肾病分层。

主要发现

  • 合并慢性肾病患者完全应答率为37.6%,无慢性肾病者为45.6%(P = .201)。
  • 慢性肾病对特利加压素治疗应答无影响(sHR 0.80,95%CI 0.58-1.10;P = .171)。
  • 仅血清肌酐变化值与完全应答显著相关(sHR 0.59,95%CI 0.47-0.74;P < .001)。
  • 总体并发症无差异(19.8% vs 15.3%;P = .350),但慢性肾病组肺水肿更多(5.9% vs 1.7%;P = .036)。
  • 30天死亡率(32.7% vs 28.6%;P = .450)、1年死亡率(43.6% vs 41.5%;P = .727)及随访期需肾脏替代治疗比例(26.7% vs 22.8%;P = .498)两组相似。

关键数值与推荐

  • 完全应答率:慢性肾病组37.6% vs 无慢性肾病组45.6%(P = .201)。
  • 慢性肾病对治疗应答的sHR为0.80(95%CI 0.58-1.10;P = .171)。
  • 血清肌酐变化值与完全应答的sHR为0.59(95%CI 0.47-0.74;P < .001)。
  • 肺水肿发生率:慢性肾病组5.9% vs 无慢性肾病组1.7%(P = .036)。
  • 调整MELD评分和治疗应答后,慢性肾病对生存影响的sHR为1.08(95%CI 0.63-1.72;P = .759)。

临床怎么用

  • 合并慢性肾病的HRS-AKI患者仍可使用特利加压素联合白蛋白治疗。
  • 治疗期间需警惕慢性肾病患者肺水肿风险增加。

局限性

  • 回顾性观察性设计可能存在混杂偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Efficacy of treatment with terlipressin and its impact on outcome in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI) and chronic kidney disease (CKD) is unknown. This multicenter, retrospective, observational study aimed to investigate treatment response of terlipressin (+ albumin) in patients with HRS-AKI and CKD compared with patients without CKD. METHODS: A total of 395 patients who received albumin/terlipressin were retrospectively analyzed and stratified according to presence of CKD at baseline. The primary endpoint was a complete response to terlipressin treatment. Secondary endpoints included adverse events, need for renal replacement therapy and 12-month liver transplantation-free survival. RESULTS: A total of 37.6% of patients with CKD and 45.6% of patients without CKD (P = .201) had complete treatment response. CKD had no influence on treatment response to terlipressin (subdistribution hazard ratio [sHR], 0.80 [95% confidence interval (CI), 0.58-1.10]; P = .171). Only delta serum creatinine was significantly associated with complete treatment response to terlipressin (sHR, 0.59 [95% CI, 0.47-0.74]; P < .001) without more complications overall (19.8% vs 15.3%; P = .350). However, patients with CKD had more pulmonary edema (5.9% vs 1.7%; P = .036). Mortality (30 days: 32.7% vs 28.6%; P = .450; 1 year: 43.6% vs 41.5%; P = .727) as well as need for renal replacement therapy during follow-up (26.7% vs 22.8%; P = .498) was similar between groups. After adjusting for Model for End-Stage Liver Disease score and treatment response, CKD did not impact survival in patients with HRS-AKI (sHR, 1.08 [95% CI, 0.63-1.72]; P = .759) considering liver transplantation as competing event. CONCLUSIONS: CKD does not adversely affect treatment response to terlipressin or survival in patients with HRS-AKI. CLINICALTRIALS: gov, Number: NCT06161766.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Uschner FE, Schleicher EM, Passenberg M, et al. Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome-Acute Kidney Injury. Clin Gastroenterol Hepatol. 2025. PMID: 41265546. doi:10.1016/j.cgh.2025.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。